1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: B1931008, 3129K5-3303, NCT01232556
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: B1931022, NCT01564784
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: 2010-0991, NCT01371630
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: CMC-R-GEMOX, 2011-003849-18, NCT01562990
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-0265, NCT01664910
|
|
6.
|
Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: UCL 11/0475, NCT01679119
|
|
7.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3129K2-1105, B1931003, NCT01055496
|
|
8.
|
Phase: Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2009-0872, NCT01134575
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: B1931010, 3129K6-1106, NCT01363297
|
|
10.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: IOSI-LND-001, NCT01535989
|